Volume 6 Issue 1
Jan.  2015
Turn off MathJax
Article Contents
Li YUAN, Huan-wen WU, Xin-yu REN, Zhi-yong LIANG. Difference in Clinicopathological Features of Triple Negative Breast Cancer and Non-triple Negative Breast Cancer and Relationship between Clinicopathological Features and Expressions of Estrogen Receptor β/Epidermal Growth Factor Receptor[J]. Medical Journal of Peking Union Medical College Hospital, 2015, 6(1): 1-8. doi: 10.3969/j.issn.1674-9081.2015.01.001
Citation: Li YUAN, Huan-wen WU, Xin-yu REN, Zhi-yong LIANG. Difference in Clinicopathological Features of Triple Negative Breast Cancer and Non-triple Negative Breast Cancer and Relationship between Clinicopathological Features and Expressions of Estrogen Receptor β/Epidermal Growth Factor Receptor[J]. Medical Journal of Peking Union Medical College Hospital, 2015, 6(1): 1-8. doi: 10.3969/j.issn.1674-9081.2015.01.001

Difference in Clinicopathological Features of Triple Negative Breast Cancer and Non-triple Negative Breast Cancer and Relationship between Clinicopathological Features and Expressions of Estrogen Receptor β/Epidermal Growth Factor Receptor

doi: 10.3969/j.issn.1674-9081.2015.01.001
More Information
  • Corresponding author: LIANG Zhi-yong Tel: 010-69159369, E-mail:liangzy@pumch.cn
  • Received Date: 2014-03-21
  • Publish Date: 2015-01-30
  •   Objective  To analyze the differences in clinicopathologic features and expressions of some immunohistochemical indicators between triple negative breast cancer and non-triple negative breast cancer, and to investigate the relationship between clinicopathological features and immunohistochemical indicators.  Methods  A total of 863 patients (135 triple negative breast cancer and 728 non-triple negative breast cancer) with histopathologically confirmed breast cancer were collected in Peking Union Medical College Hospital from January 2010 to December 2013.We retrospectively analyzed the difference in the onset age, histological subtype, tumor size, tumor differentiation, tumor stages, lymph node metastasis, nipple involvement and operation method between triple negative breast cancer and non-triple negative breast cancer, then explored the difference between them in the expressions of estrogen receptor β (ERβ), epidermal growth factor receptor (EGFR), P53, and Ki67 by immunohistochemical staining. Prognostic factors of triple negative breast cancer were further discussed by univariate survival analysis.  Results  The proportion of invasive ductal carcinoma in triple negative breast cancer was higher than that in non-triple negative breast cancer (86.7% vs. 65.2%, P < 0.001); the age of onset was younger in triple negative breast cancer[(46.0±10.6) years vs. (51.0±3.3) years, P < 0.05];significant differences were also found in lymph node metastasis, tumor size, differentiation grade, surgical procedure, and tumor stages between the two groups(P < 0.05); no statistically significant inter-group difference in nipple involvement (P > 0.05). Immunohistochemical results showed that compared with non-triple negative breast cancer, ERβ expression rate decreased significantly(63.7% vs. 75.6%, P < 0.05)while EGFR expression rate increased significantly in triple negative breast cancer(62.2% vs. 33.3%, P < 0.05); the expression of P53 and Ki67 demonstrated no significant difference(P > 0.05). The overall survival(OS)and relapse-free survival(RFS)were both lower in triple negative breast cancer(P < 0.05). Univariate survival analysis showed that both ERβ negative expression and EGFR positive expression were related to the poor prognosis of triple negative breast cancer (P < 0.05).  Conclusions  Compared with non-triple negative breast cancer, triple negative breast cancer shows completely different clinicopathological features:younger age of onset, larger tumor size, lower degree of differentiation, higher incidence of lymph node metastasis, lower ERβ expression, higher EGFR expression, and lower OS and RFS.ERβ and EGFR may be important prognostic indicators in triple negative breast cancer.
  • loading
  • [1] Zheng G, Peng F, Ding R, et al. Identification of proteins responsible for the multiple drug resistance in 5-fluorouracil-induced breast cancer cell using proteomics analysis[J]. Cancer Res Clin Oncol, 2010, 136:1477-1488. doi:  10.1007/s00432-010-0805-z
    [2] Perou CM, Softie T, Eisen MB, et al. Molecular portraits of human breast turnouts[J].Nature, 2000, 406:747-752. doi:  10.1038/35021093
    [3] Strehl JD, Wachter DL, Fasching PA, et al. Invasive breast cancer:recognition of molecular subtypes[J]. Breast Care(Basel), 2011, 6:258-264. http://europepmc.org/articles/PMC3225209/
    [4] Dent R, Trudeau M, Pritchard KJ, et al. Triple negative breast cancer:features and patterns of recurrence[J]. Clin Cancer Res, 2007, 13:4429-4434. doi:  10.1158/1078-0432.CCR-06-3045
    [5] Abkevich V, Timms K, Hennessy B, et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer[J]. Br J Cancer, 2012, 107:1776-1782. doi:  10.1038/bjc.2012.451
    [6] Van den Akker EB, Verbruggen B, Heijmans BT, et al.Integrating protein-protein interaction networks with gene-gene co-expression networks improves gene signatures for classifying breast cancer metastasis[J]. Integr Bioinform, 2011, 8:188. http://europepmc.org/abstract/MED/22180387
    [7] Carey LA, Dees EC, Sawyer L, et al.The triple negative paradox:primary tumor chemosensitivity of breast cancer subtypes[J].Clin Cancer Res, 2007, 13:2329-2334. doi:  10.1158/1078-0432.CCR-06-1109
    [8] Bauer KR, Brown M, Cress RD, et al.Descriptive analysis of estrogen receptor(ER)-negative, progesterone receptor(PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype:a population-based study from the California cancer Registry[J].Cancer, 2007, 109:1721-1728. doi:  10.1002/cncr.22618
    [9] Wirapati P, Sotirlou C, Kunkel S, et al.Meta-analysis of gene expression profiles in breast cancer:toward a unified understanding of breast cancer subtyping and prognosis signatures[J]. Breast Cancer Res, 2008, 10:R65. doi:  10.1186/bcr2124
    [10] Kuiper GG, Enmark E, Pelto-Huikko M, et al. Cloning of a novel receptor expressed in rat prostate and ovary[J]. Proc Natl Acad Sci USA, 1996, 93:5925. doi:  10.1073/pnas.93.12.5925
    [11] Cuzick J, Dowsett M, Pineda S, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer[J]. J Clin Oncol, 2011, 29:4273-4278. doi:  10.1200/JCO.2010.31.2835
    [12] Murphy LC, Leygue E. The role of estrogen receptor-β in breast cancer[J]. Semin Reprod Med, 2012, 30:5-13. doi:  10.1055/s-0031-1299592
    [13] Murphy LC, Leygue E. A bi-faceted role of estrogen receptor β in breast cancer[J]. Endocri Relat Cancer, 2013, 20:R127-R139. doi:  10.1530/ERC-12-0389
    [14] Speirs V, Malone C, Walton DS, et al. Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients[J]. Cancer Res, 1999, 59:5421-5424. http://europepmc.org/abstract/med/10554009
    [15] Sugiura H, Toyama T, Hara Y, et al. Expression of estrogen receptor β wild-type and its variant ER-βcx/β2 is correlated with better prognosis in breast cancer[J]. Jpn J Clin Oncol, 2007, 37:820-828. doi:  10.1093/jjco/hym114
    [16] Corkery B, Crown J, Clynes M, et al. Epidermal growth factor receptor as a potential therapeutic target in triple negative breast cancer[J].Ann Oncol, 2009, 20:862-867. doi:  10.1093/annonc/mdn710
    [17] Ulivi P, Zoli W, Capelli L, et al. Target therapy in NSCLC patients:relevant clinical agents and tumor molecular characterization[J]. Mol Clin Oncol, 2013, 7:575-581. http://www.onacademic.com/detail/journal_1000038007664910_bf8d.html
    [18] Nielsen TO, Hsu FD, Jensen K, et al.Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma[J].Clin Cancer Res, 2004, 10:5367-5374. doi:  10.1158/1078-0432.CCR-04-0220
    [19] Davidoff AM, Herndon JE, Glover NS, et al.Relation between p53 over expression and established prognostic factors in breast cancer[J].Surgery, 1991, 110:259-264. http://www.ncbi.nlm.nih.gov/pubmed/1858036
    [20] Bhatavdekar JM, Patel DD, Shah NG, et al.Prognostic significance of immunohistochemically localized biomarkers in stageⅡ and stage Ⅲ breast cancer:a multivariate analysis[J]. Ann Surg Oncol, 2000, 7:305-311. doi:  10.1007/s10434-000-0305-5
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(10)  / Tables(3)

    Article Metrics

    Article views (111) PDF downloads(3) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return